MX2013000729A - Composiciones ciclopolisacárido anionico-catiónico y bendamustina. - Google Patents

Composiciones ciclopolisacárido anionico-catiónico y bendamustina.

Info

Publication number
MX2013000729A
MX2013000729A MX2013000729A MX2013000729A MX2013000729A MX 2013000729 A MX2013000729 A MX 2013000729A MX 2013000729 A MX2013000729 A MX 2013000729A MX 2013000729 A MX2013000729 A MX 2013000729A MX 2013000729 A MX2013000729 A MX 2013000729A
Authority
MX
Mexico
Prior art keywords
bendamustine
catioinic
anionic
cyclopolysaccharide
compositions
Prior art date
Application number
MX2013000729A
Other languages
English (en)
Other versions
MX341356B (es
Inventor
Valery Alakhov
Grzegorz Pietrzynski
Kishore Patel
Tomasz Popek
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Publication of MX2013000729A publication Critical patent/MX2013000729A/es
Publication of MX341356B publication Critical patent/MX341356B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención esta dirigida a composiciones farmacéuticas incluyendo: (a) bendamustina, (b) u primer ciclopolisacarido cargado y (c) un agente estabilizante el cual es un segundo ciclopolisacárido cargado teniendo una carga opuesta aquella del primer ciclopolisacárido cargado. La composición proporciona una estabilidad inesperadamente deseable en ambientes reactivos tal como plasma acoplado con una actividad anticáncer inesperadamente deseable. Las composiciones son adecuadas para la inyección o infusión en pacientes en la necesidad para el tratamine5to con bendamustina.
MX2013000729A 2010-07-19 2011-02-23 Composiciones ciclopolisacárido anionico-catiónico y bendamustina. MX341356B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39985510P 2010-07-19 2010-07-19
US13/032,168 US8383663B2 (en) 2010-07-19 2011-02-22 Bendamustine anionic-catioinic cyclopolysaccharide compositions
PCT/IB2011/003367 WO2012127277A2 (en) 2010-07-19 2011-02-23 Bendamustine anionic-catioinic cyclopolysaccharide compositions

Publications (2)

Publication Number Publication Date
MX2013000729A true MX2013000729A (es) 2013-07-17
MX341356B MX341356B (es) 2016-07-07

Family

ID=45467434

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000729A MX341356B (es) 2010-07-19 2011-02-23 Composiciones ciclopolisacárido anionico-catiónico y bendamustina.

Country Status (11)

Country Link
US (1) US8383663B2 (es)
EP (1) EP2595660B1 (es)
JP (1) JP5788982B2 (es)
KR (2) KR101874764B1 (es)
CN (1) CN103228296B (es)
AU (3) AU2011363446B2 (es)
BR (1) BR112013001462B8 (es)
CA (1) CA2805805C (es)
MX (1) MX341356B (es)
RU (1) RU2647368C2 (es)
WO (1) WO2012127277A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108997514B (zh) * 2017-06-06 2021-06-08 首都医科大学 单-6-(苯达莫司汀酰胺基)-6-脱氧-β-环糊精的制备和应用
AU2018346395A1 (en) 2017-10-05 2020-04-30 Mecox Curemed Co., Ltd. Oral bendamustine formulations
CN111557904A (zh) * 2020-04-09 2020-08-21 比卡生物科技（广州）有限公司 苯达莫司汀组合物及其用途
WO2021203377A1 (zh) * 2020-04-09 2021-10-14 比卡生物科技（广州）有限公司 苯达莫司汀组合物及其用途
US11970977B2 (en) 2022-08-26 2024-04-30 Hamilton Sundstrand Corporation Variable restriction of a secondary circuit of a fuel injector
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5068226A (en) 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
JPH04500229A (ja) * 1988-08-31 1992-01-16 オーストレイリアン・コマーシヤル・リサーチ・アンド・デイベロツプメント・リミテツド 薬剤分配用及びクロマトグラフィー用の組成物及び方法
MY106598A (en) 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JP4608031B2 (ja) 1997-03-13 2011-01-05 ヘキサル アーゲー アミノ酸／シクロデキストリン混合物による酸感受性ベンズイミダゾール類の安定化
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
ATE251466T1 (de) 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
GB9921958D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
JP2005521691A (ja) 2002-02-22 2005-07-21 ファルマシア・コーポレーション シクロデキストリン化合物及び塩化セチルピリジニウムを含有する眼科用抗菌性薬物製剤
PT1499361E (pt) 2002-04-19 2012-11-22 Novartis Ag Novos biomateriais, sua preparação e utilização
SI1542668T1 (sl) * 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
WO2006027631A1 (en) * 2004-09-10 2006-03-16 National Center For Scientific Research 'demokritos' Neapoleos & Patriarchou Gregoriou Per-6-guanidino-, -aminoalkylamino-and -guanidino-alkylamino-cyclodextrins, methods of their synthesis and their use for the compaction of dna and interacellular delivery
EP1814544A4 (en) * 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1848813B1 (en) 2005-01-28 2013-04-10 Brigham Young University Bacterial glycolipid activation of cd1d-restricted nkt cells
EP1760467A1 (en) 2005-09-02 2007-03-07 Schering AG Optically fluorescent nanoparticles
CN1846685A (zh) 2006-01-25 2006-10-18 济南帅华医药科技有限公司 含苯达莫司汀和其增效剂的缓释注射剂
WO2008106721A1 (en) 2007-03-02 2008-09-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
CN101219113A (zh) 2008-01-28 2008-07-16 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
CA2753641C (en) 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
CN101606934B (zh) 2009-07-27 2011-09-28 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
CN101897977A (zh) 2010-07-29 2010-12-01 浙江大学 离子型环糊精衍生物在制备用于离子导入透皮给药的药物制剂中的应用

Also Published As

Publication number Publication date
BR112013001462B1 (pt) 2022-04-19
WO2012127277A2 (en) 2012-09-27
BR112013001462A2 (pt) 2016-05-31
CN103228296B (zh) 2015-04-08
KR20130113428A (ko) 2013-10-15
CN103228296A (zh) 2013-07-31
US20120015995A1 (en) 2012-01-19
AU2011363446A1 (en) 2013-02-21
CA2805805C (en) 2018-10-23
JP2013531060A (ja) 2013-08-01
CA2805805A1 (en) 2012-09-27
US8383663B2 (en) 2013-02-26
AU2019219792A1 (en) 2019-09-12
JP5788982B2 (ja) 2015-10-07
KR101874764B1 (ko) 2018-07-04
EP2595660A2 (en) 2013-05-29
AU2019219792B2 (en) 2023-03-02
WO2012127277A3 (en) 2013-03-14
RU2013107115A (ru) 2014-08-27
KR20170102061A (ko) 2017-09-06
KR101807903B1 (ko) 2017-12-12
AU2017216568A1 (en) 2017-09-14
AU2011363446B2 (en) 2017-05-18
EP2595660B1 (en) 2015-07-22
MX341356B (es) 2016-07-07
EP2595660A4 (en) 2014-01-01
RU2647368C2 (ru) 2018-03-15
BR112013001462B8 (pt) 2022-08-02

Similar Documents

Publication Publication Date Title
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
NZ732507A (en) Improved compositions for treating muscular dystrophy
NZ707203A (en) Triazolopyrazine
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
MD4602B1 (ro) Inhibitori ai virusului hepatic C
SG10201907684PA (en) Androgen receptor modulator and uses thereof
NZ608116A (en) Triazine-oxadiazoles
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2013000729A (es) Composiciones ciclopolisacárido anionico-catiónico y bendamustina.
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
MY162146A (en) Pharmaceutical composition
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2013004061A (es) Analogos de ciclosporina.
IN2014DN08598A (es)
EP4360621A3 (en) Formulations of bendamustine
MX2015004362A (es) Derivados de ketamina.
IN2014DN06869A (es)
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX2013004062A (es) Analogos de ciclosporina.
MX2013013079A (es) Composiciones que comprenden un agente antibacterial y tazobactam.
IN2013MU01157A (es)
NZ626495A (en) Treatment of type i and type ii diabetes

Legal Events

Date Code Title Description
FG Grant or registration